膀胱癌发病率与死亡率:全球概览及近期趋势
该研究基于GLOBOCAN 2022年185个国家数据及人群癌症登记资料,描述全球膀胱癌发病与死亡的地理差异和近期趋势。2022年全球估计新发614298例、死亡220596例,约75%负担在男性;欧洲南部发病率最高(ASR 28.7),许多高收入国家发病率趋稳或下降,死亡率总体下降但部分地区上升。
要点
- 2022年全球膀胱癌新发614298例、死亡220596例,约75%在男性。
- 欧洲南部发病率最高(ASR 28.7),东亚绝对病例数最多。
- 许多高收入国家发病率趋稳或下降,死亡率总体下降但部分地区上升。
核心结论
- 膀胱癌仍是全球重要健康挑战,发病与死亡存在明显地理和性别差异。
- 许多高收入国家发病率趋稳或下降,但负担仍大且部分地区上升。
- 吸烟是主要风险因素,北非血吸虫感染导致发病升高和独特组织学类型。
研究设计与样本
- 基于GLOBOCAN 2022年185个国家按性别的膀胱癌发病和死亡估计。
- 发病和死亡记录数据来自五大洲癌症发病率系列和世界卫生组织数据库。
- 采用直接标准化(世界标准)计算每10万人年年龄标化率(ASR),用估计年度百分比变化(EAPC)量化近期趋势。
主要发现
- 2022年全球估计新发膀胱癌614298例、死亡220596例,约75%负担在男性。
- 尿路上皮癌和鳞状细胞癌是所有地区主要组织学亚型。
- 欧洲南部(ASR 28.7)和北部(20.4)发病率最高,北美(18.0)、北非(16.3)和西亚(15.2)也较高。
- 东亚年龄标化率较低但因人口多绝对病例数最高。
- 死亡率在许多人群下降,如澳大利亚男性EAPC -2.6、女性-2.3;荷兰男性2.9、女性-1.6;美国男性-1.3、女性-1.0。
关键数值与推荐
- 2022年全球膀胱癌新发614298例、死亡220596例。
- 欧洲南部ASR 28.7、北部20.4、北美18.0、北非16.3、西亚15.2。
- 澳大利亚男性死亡率EAPC -2.6、女性-2.3;荷兰男性2.9、女性-1.6;美国男性-1.3、女性-1.0。
临床怎么用
- 解读膀胱癌发病率和趋势需注意登记实践差异,尤其是非浸润性肿瘤是否纳入报告。
- 吸烟仍是主要风险因素,历史与当前吸烟模式与疾病趋势密切相关。
- 北非血吸虫感染贡献较高发病率和独特组织学特征,需结合地区病因学背景。
局限性
- 癌症登记实践可能存在差异,特别是非浸润性肿瘤的报告与否。
- 发病率和趋势解读需谨慎,因登记实践变异可能影响可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Bladder cancer is the most common tumor of the urinary tract and the ninth most common cancer worldwide. Our objective was to describe and interpret current geographic variations in bladder cancer incidence and mortality rates using updated national estimates and recorded data from population-based cancer registries alongside national vital statistics. METHODS: The bladder cancer incidence and mortality for 185 countries by sex were obtained from GLOBOCAN (International Agency for Research on Cancer) for the year 2022. Recorded incidence and mortality data were retrieved from national or subnational population-based cancer registries included in the Cancer Incidence in Five Continents series and the World Health Organization database, respectively. Corresponding age-standardized rates (ASRs) per 100000 person-years were calculated using direct standardization (world standard), and temporal trends of ASRs by calendar period and sex are presented by country, with the direction and magnitude of recent trends quantified using the estimated annual percentage change (EAPC). KEY FINDINGS AND LIMITATIONS: In 2022, an estimated 614298 new cases of bladder cancer and 220596 deaths occurred worldwide, with approximately 75% of the burden observed in males. Urothelial and squamous cell carcinomas were the predominant histological subtypes across all regions. Incidence and mortality rates varied substantially across regions and countries, with the highest rates reported in Europe, particularly in southern (ASR: 28.7) and northern (20.4) regions, and elevated rates were also seen in North America (18.0), Northern Africa (16.3), and Western Asia (15.2). Despite lower age-standardized rates, Eastern Asia reported the highest absolute numbers due to its large population. Temporal trends indicate a stabilizing or declining incidence in many high-income countries. Mortality rates have overall declined across many populations, for example, in Australia (EAPC in male: -2.6; female: -2.3), the Netherlands (male: 2.9; female: -1.6), and the USA (male: -1.3; female: -1.0). Interpretation of bladder cancer incidence patterns and trends requires caution given possible variations in cancer registration practice, notably as to whether noninvasive tumors are included in reporting. CONCLUSIONS AND CLINICAL IMPLICATIONS: Bladder cancer continues to pose a significant global health challenge, with marked geographic and sex-based disparities in the incidence and mortality. While encouraging declines in rates are observed in many high-income countries, the burden remains substantial in these regions and rates are rising in some settings. Tobacco smoking remains the predominant risk factor, with historical and current prevalence patterns aligned closely with disease trends. However, in Northern Africa, schistosomiasis contributes to an elevated incidence and a distinct histological profile. Interpretation of these patterns is complex given the potential variations in registration practice, with respect to reporting of noninvasive tumors.
引用
- Filho AM, Briganti A, Jemal A, et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2025. PMID: 41421927. doi:10.1016/j.eururo.2025.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。